Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,382.00up ₹83.30 (3.62%)BSE ₹2,388.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹2,298.70.
2 Nov: open ₹2,306.00, high ₹2,400.10, low ₹2,306.00
52-week range of traded prices to 2 Nov 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹67,226 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 37.39
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.97
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.40
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 15,49,67347.5% delivered
Glenmark Pharmaceuticals share news and announcements
1,381 announcements, routine notices left out, newest first. Page 21 of 28.
May 2012
Apr 2012
27 Apr · Board meeting
(1) To consider and approve the Company's Audited Financial Statements for the Year ended March 31, 2012; (2) To consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2012.
Mar 2012
16 Mar · Business
Board of Directors of the Company, at its Operation Committee Meeting held on March 16, 2012 allotted 20,450 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Feb 2012
15 Feb · Business
Board of Directors of the Company, at its Meeting held on February 14, 2012, allotted 93,650 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Jan 2012
30 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2011 as follows: Net Sales of Rs. 39688 lacs for quarter ending on 31-DEC-2011 against Rs. 31838.65 lacs for the quarter ending on 31-DEC-2010. Net Profit / (Loss) of Rs. 1314.1 lacs for the quarter ending on 31-DEC-2011 against Rs. 5794.76 lacs for the quarter ending on 31-DEC-2010.19 Jan · Board meeting
To consider and approve the Un-Audited Financial Results for the third quarter ended December 31, 2011.
Dec 2011
23 Dec · Business
Board of Directors of the Company, at its Operations Committee Meeting held on December 23, 2011 allotted 8,650 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.13 Dec · Updates
On Aug 8, 2011, Glenmark filed a statement of claim with the American Arbitration Association against Napo Pharmaceuticals seeking, among other things, a declaration that Glenmark's exclusive rights to develop, commercialise and distribute Crofelemer in 140 countries for treatment of diarrhoeal diseases includes the exclusive rights to distribute though relief agencies in these countries. Glenmark recognises the importance of relief agency distribution of Crofelemer to populations in emerging countries with the most critical need for the product. Glenmark believes that contractually it has exclusive rights with respect to relief agency distribution in the countries and indications licensed to Glenmark. Napo Pharmaceuticals, Inc. recently issued a press release in which it claims to have terminated a July 02, 2005 Collaboration Agreement between it and Glenmark Pharmaceuticals Ltd. With respect to the Collaboration Agreement relating Crofelemer - Glenmark vehemently denies that Napo has any basis for terminating the Collaboration Agreement, and Glenmark is seeking a declaration from an arbitration panel that Napo's claims of breach are unfounded. On December 09, 2011, Glenmark formally requested that the arbitration panel issue an interim order directing Napo to comply with the Collaboration Agreement during the pendency of the arbitration12 Dec · Disclosure
Compensation Committee of the Company, at its meeting held on December 07, 2011 has issued 25,000 stock options to permanent employees pursuant to ESOS 2003. Each option shall be convertible into one equity share of Re.1/- each in one or more tranches.6 Dec · Updates
Glenmark Generics Limited, subsidiary of Glenmark Pharmaceuticals Limited, has announced that it made a payment of USD 28.8 million in exercise of its purchase option election with respect to its royalty agreement with Paul Capital Partner's Royalty Fund("Paul Capital"). As stated in the June 2005 release when the deal was entered, Paul Capital invested funds for the development of dermatological products for the US market. In return, Paul Capital received royalties. With the exercise of the purchase option election, Glenmark Generics Limited has no further obligation to pay royalties to Paul Capital.
Nov 2011
11 Nov · Board meeting
Mr. R. V. Desai, CFO has been appointed as Executive Director at the Board Meeting held on November 09, 2011.11 Nov · Business
Board of Directors of the Company, at its Meeting held on November 09, 2011, allotted 33,950 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.9 Nov · Outcome of meeting
Compensation Committee of the Company, at its meeting held on November 09, 2011 has cancelled 2,79,950 stock options pursuant to ESOS 2003, owing to employees leaving the services of the Company.9 Nov · Results
Standalone Results for the quarter ended on 30-SEP-2011 as follows: Net Sales of Rs. 37643.2 lacs for quarter ending on 30-SEP-2011 against Rs. 29316.7 lacs for the quarter ending on 30-SEP-2010. Net Profit / (Loss) of Rs. 3146 lacs for the quarter ending on 30-SEP-2011 against Rs. 2754.29 lacs for the quarter ending on 30-SEP-2010.7 Nov · Updates
Glenmark Pharmaceuticals S.A (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announced on November 07, 2011 that it has received from Sanofi a USD 5 million milestone payment related to the successful completion of the Phase I clinical study of GRC 15300. a first-in-class TRPV3 inhibitor for treatment of pain.
Oct 2011
25 Oct · Board meeting
To consider the Un-Audited Financial Results for the Q2 / Half year ended September 30, 2011.
Sep 2011
30 Sep · Updates
Glenmark Generics Ltd, a subsidiary of Glenmark Pharmaceuticals Ltd, has announced that it made a payment of USD 28.8 million in exercise of its purchase option election with respect to its royalty agreement with Paul Capital Partners' Royalty Fund ("Paul Capital"). As stated in the June 2005 release when the deal was entered, Paul Capital invested funds for the development of dermatological products for the US market. In return, Paul Capital received royalties. With the exercise of the purchase option election, Glenmark Generics Ltd has no further obligation to pay royalties to Paul Capital.2 Sep · Business
Board of Directors of the Company, at its Operations Committee Meeting held on August 30, 2011, allotted 26,050 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Aug 2011
11 Aug · Meeting
At the Annual General Meeting held on August 11, 2011, the Shareholders have approved the following : Dividend of Re. 0.40 per share of Re.1 each (40%) on the Equity Share Capital of the Company for the financial year ended 2010-2011.
Jul 2011
27 Jul · Business
Board of Directors of the Company, at its Meeting held on July 26, 2011, alloted 21,000 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.26 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 32330.2 lacs for quarter ending on 30-JUN-2011 against Rs. 25700.02 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 7246.5 lacs for the quarter ending on 30-JUN-2011 against Rs. 6079.11 lacs for the quarter ending on 30-JUN-2010.26 Jul · Results
18 Jul · Meeting
Register of Members and the Share Transfer Books of the Company will remain closed from August 01, 2011 to August 11, 2011 (both days inclusive) for the purpose of the Annual Closure for the Annual General Meeting scheduled to be held on August 11, 2011 and also for determining the names of the shareholders to whom the dividend which if declared at the Annual General Meeting is payable.18 Jul · Updates
The, "Glenmark Generics today announced they have been granted final approval for their abbreviated new drug application (ANDA) by the United States Food and Drug Administration (U.S. FDA) for Nizatidine Capsules and will commence marketing immediately. Nizatidine capsules are Glenmark's generic version of Axid by Smithkline Beecham Corporation and are indicated for up to 8 weeks for the treatment of active duodenal ulcer."